July 15: The preparation of Phase III clinical trial samples for the hepatocyte growth factor naked plasmid injection has been completed.

October 12: The kickoff meeting for the Phase I multiple-dose clinical trial of recombinant human thymosin β4 for injection was held.

November 25: The investigator’s protocol discussion meeting for the Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection was held.

December 18: The signing ceremony for the company’s Series C funding round was held at Tasly Group.

July 10: The Phase I clinical trial of recombinant human thymosin β4 for injection officially commences.

October: The recombinant human hepatocyte growth factor naked plasmid injection was approved for Phase III clinical trials.

December: The NL005 project has once again been approved as a key national special project for the development of new drugs.

January 28: NORTHLAND Invited to Attend the China-Korea FTA Investment Forum

June 8: The holding subsidiary, Huonland Company, obtained the registration certificate for ophthalmic solution packaging materials.

June 8: The holding subsidiary, Huonland Company, obtained clinical trial approval for moxifloxacin hydrochloride eye drops.

August 9: The holding subsidiary Huonland has been granted the approval number for brimonidine tartrate.

August 17: NORTHLAND Selected for Beijing's Biopharmaceutical Industry "G20 Project"

September 14: Holding subsidiary Huonland makes its debut at the 21st National Ophthalmology Annual Conference.

October 31: NORTHLAND was awarded the title of "50 Most Worthwhile Pharmaceutical Companies on the New Third Board in 2016."

November 11: Huonland partners with the Institute of Materia Medica, Chinese Academy of Medical Sciences, to establish a joint R&D base for ophthalmic drugs.

November 15: The holding subsidiary, Huonland, has been awarded the “Drug GMP Certificate.”

March 18: NORTHLAND Selected as a Constituent Stock of the First Batch of the New Third Board Index

August 13: Signed a technology transfer agreement with South Korean company HUONS for rhTβ4 technology.

December 15: Recombinant human thymosin β4 receives clinical trial approval (Phase I/II).

December 15: “Thymosin β4 Derivatives and Their Applications” (Patent No. ZL200680025339.0) was awarded the “China Patent Excellence Award” by the National Intellectual Property Administration.

March 22: NORTHLAND signs a strategic cooperation agreement with Pangen Co., Ltd. (Korea)

April 17: The recombinant human coagulation factor VIII project has received the Notice of Acceptance for New Drug Clinical Trials from the National Medical Products Administration, and is intended for the prophylactic and replacement treatment of hemophilia A.

July 18: The newly built pharmaceutical plant of Beijing Huonland Pharmaceutical Technology Co., Ltd. was completed and put into operation.

August 27: Beijing Huonland Pharmaceutical Technology Co., Ltd. obtained a drug production license.

December 4: On December 4, 2014, the company was honored with the title of “Top 50 Most Investment-Valuable Companies in China—9th Edition” by Qichacha.

December 12: The company won the “Annual Best Performance Award” in the “Huaxin Award” selection held by First Finance’s New Third Board.

May 30: The main structure of Phase I of the NORTHLAND pharmaceutical production base has been topped out.

June 24: NORTHLAND was selected as a key high-tech enterprise under the National Torch Program.

December 4: Xu Songshan, Chairman of the company, was awarded the “2013 Zhongguancun Entrepreneurial Star” title.

December 17: Recombinant human thymosin β4 receives the Clinical Trial Acceptance Notice from the National Medical Products Administration.

March 28: The NL002 project has received approval for Phase III clinical trials.

May 20: The company was recognized as the Beijing Naked Plasmid Gene Therapy Drug Engineering Technology Research Center.

June 15: The company held a groundbreaking ceremony for the construction of its pharmaceutical production base project.